ArticleKidney international reports2022
Challenges in Diagnosis and Management of Glomerular Disease in Resource-Limited Settings.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Artificial intelligence-powered renal pathology for glomerular disease classification: a systematic review and meta-analysis.Renal failure · 2026Pooled it
- Prevalence and distribution of primary glomerular diseases in Africa: a systematic review and meta-analysis of observational studies.The Pan African medical journal · 2023Pooled it
- Exploring the global, regional, and Chinese disease burden of acute glomerulonephritis from 1990 to 2021 and future trends up to 2039 based on the 2021 Global Burden of Disease Database.International urology and nephrology · 2026Article
- Deep Learning Enables Automated Segmentation and Quantification of Ultrastructure from Transmission Electron Microscopy Images.bioRxiv : the preprint server for biology · 2026Article
- Leveraging extracellular vesicle biology for novel tests and therapeutics for kidney fibrosis.Clinical and translational medicine · 2026Review
- Exploring Deep Learning Models for Small Histopathology Datasets: Segmentation and Classification of Glomerular Crescent Lesions with Ablation, Interpretability, and Calibration Analyses.Interdisciplinary sciences, computational life sciences · 2026Article
- New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.Kidney medicine · 2025Review
- Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy.Kidney international reports · 2025Article
- Diagnostic approach to glomerular diseases: integrating clinical, laboratory, and histopathological assessments.Annals of medicine and surgery (2012) · 2025Review
- Inequities in kidney health and kidney care.Nature reviews. Nephrology · 2023Review
- Trends in the Global Burden of Glomerulonephritis.Clinical journal of the American Society of Nephrology : CJASN · 2023Article
- Atypical presentation of syphilis: Rapidly progressive glomerulonephritis.Clinical case reports · 2023Article
- Indian TrANslational GlomerulonephrItis BioLogy nEtwork (I-TANGIBLE): Design and Methods.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glomerular diseases are the leading drivers of nondiabetic chronic kidney disease disability-adjusted life years in resource-limited countries. Proper diagnosis and treatment relies on resources including kidney biopsy, ancillary testing, and access to evidence-based therapies. Methods: We conducted a cross-sectional internet-based survey cascaded through society mailing lists among nephrologists in countries of Asia, Africa, and Eastern Europe. We collected the data on respondent demographics, their ability to perform and appropriately interpret a kidney biopsy, and their access to complementary investigations and treatment practices. Results: A total of 298 kidney care specialists from 33 countries (53.3% from Asia and 44.6% from Africa; 64% from academic or university hospitals) participated in the survey. Of these specialists, 85% performed kidney biopsy. About 61% of the respondents could not obtain a kidney biopsy in more than 50% of patients with suspected glomerular disease. About 43% of the respondents from Africa had access to only light microscopy. Overall, the inability to undertake and fully evaluate a biopsy and perform ancillary investigations were more profound in Africa than in Asia. Overall, 59% of participants reported that more than 75% of their patients meet the cost of diagnosis and treatment by out-of-pocket payments. Empirical use of immunosuppression was higher in Africa than in Asia. The main barriers for diagnosis and treatment included delayed presentation, incomplete diagnostic work-up, and high cost of treatment. Conclusion: Major system-level barriers impede the implementation of guideline-driven approaches for diagnosis and treatment of patients with glomerular disease in resource-limited countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.